B. Riley FBR analyst Marc Wiesenberger initiated coverage of MTBC with a Buy rating and $6.25 price target. The company has a "low-cost, highly skilled" work force primarily in Pakistan that has enabled it to create a proprietary and innovative healthcare IT offering, Wiesenberger tells investors in a research note. Healthcare spending and the complexities associated with medical billing are both expected to increase, which bodes well for MTBC, contends the analyst. He believes the shares are undervalued and sees more than 50% potential upside from current levels.